Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

Doctor,physician,xray, teach, rare

A Rare Disease Doctor

Yesterday was national “Rare Disease Day” in the USA, with many tributes to the patients, doctors and researchers dedicated to these disorders.  Moreover, it was a great opportunity to shout about the many rare conditions that don’t often get enough press, praise or funding.

Read Article
Lupus,flare,malar,DermNetNZ

Increased SLE Flares with Hydroxychloroquine Reduction

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.

Read Article
Vaccination,vaccine

Downside of Holding Methotrexate with COVID-19 Vaccination

A recent prospective, randomized, blinded clinical trial has shown that a 2 week hold of methotrexate (MTX) following COVID-19 (Sinovac-CoronaVac) vaccination resulted in greater anti-SARS-CoV-2 immunogenicity; but there was an increase in flare rates after the second dose of vaccine.

Read Article
COVID,nasal,PCR,test,swab

MMWR - NFL Study on When to Be Released if COVID(+)

MMWR has reported the results of the National Football Leagues (NFL) change in SARS-CoV-2 testing program that went into effect in December 2021, at the height of the Omicron variant surge, showing that among those with asymptomatic infection, only half were PCR test negative and could return to

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Read Article
PSA2L.jpg

COSMOS Study - Guselkumab Efficacy at 1 Year in Psoriatic Arthritis

Guselkumab, an IL-2319-subunit antibody, was studied in active psoriatic arthritis (PsA) patients who had a previously inadequate response (IR) to tumour necrosis factor inhibitors (TNFi) and after 1 year was shown to significantly improved joint and skin manifestations and physical function.

Read Article
COVID,vaccinate,injection,green

Low COVID-19 Vaccine Risks in Rheumatic Patients

Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.

Read Article
smiley-2979107_640_0.jpg

Medscape: Physician Burnout Report 2022

The annual Medscape Physician Burnout & Depression survey has been published for 2022 and Rheumatology burnout stats have improved, now ranking 10th (middle of the pack). 

Read Article
MMWR,social,risk,factors

Increased Odds of Arthritis with Social Risk Factors

MMWR has published the results of the 2017 Behavioral Risk Factor Surveillance System showing that increases in the number of social risk factors independently increases the odds of arthritis and its burden in the USA.

Read Article
oaknees.jpg

Positive Results from the DOA (Duloxetine in OsteoArthritis) Study

A pragmatic, open-label trial of osteoarthritis (OA) patients demonstrated that adding duloxetine treatment seems to be beneficial for end-stage knee OA patients with neuropathic-like symptoms (at risk of central sensitization).

Read Article
×